ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Novartis and Pliant sign NASH deal

by Lisa M. Jarvis
October 26, 2019 | APPEARED IN VOLUME 97, ISSUE 42

 

Novartis will pay Pliant Therapeutics $80 million for access to integrin-targeted small molecules for the treatment of fibrosis. The deal includes PLN-1474, a selective inhibitor of integrin αVβ1 that Pliant is developing to address liver scarring associated with nonalcoholic steatohepatitis (NASH), and up to three drug candidates developed during the alliance. Pliant expects to ask regulators for permission to begin human tests of PLN-1474 later this year. It will conduct Phase I studies, after which Novartis will take over.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment